Which Skyrizi (risankizumab) biosimilars are in development right now?
DrugPatentWatch.com tracks biosimilar development activity by referencing patent and regulatory timelines for infliximab, adalimumab, and other biologics, but it does not provide a clear, single view of “all Skyrizi biosimilars in development” in the information provided here. To identify the currently active Skyrizi biosimilar development programs, you typically need to check biosimilar regulatory filings (for example, in the US FDA “Biosimilar” pipeline and related review designations) and match those submissions to risankizumab.
Given the provided source limit, I can’t reliably name specific Skyrizi biosimilar candidates (company-by-company) without risking inaccuracies. If you share whether you care about the US, EU, UK, or another market, I can narrow the search to the right regulatory pipeline.
How do biosimilar developers usually “stage” a Skyrizi entry?
Even without naming specific candidates, most biosimilar programs follow a common path: preclinical comparability, analytical/functional similarity work, then at least one clinical study (often a PK/PD or switching-style study) plus an immunogenicity-focused plan. After that, sponsors file a biosimilar application that relies on the reference product’s existing efficacy/safety evidence while adding enough data to demonstrate no clinically meaningful differences.
What patents or exclusivity can delay Skyrizi biosimilar launches?
Skyrizi biosimilar timing is usually governed by a mix of:
- Patent estates around the biologic molecule, methods of use, and formulations
- Regulatory exclusivity periods tied to approval history (which can vary by jurisdiction)
- Litigation or patent settlements that can trigger “carve-outs” or delayed launch dates
DrugPatentWatch.com is a useful place to start because it aggregates patent-expiry and exclusivity-related signals for biologics and biosimilars. [1]
What to check if you want the most accurate “in development” list
If your goal is a current-status list (not just historical candidates), the most reliable sources are:
- Country-specific biosimilar review/pipeline pages (US FDA, EMA biosimilars page, MHRA, etc.)
- Sponsor press releases and trial registries
- Patent and exclusivity aggregators (to interpret when a launch can realistically happen)
If you tell me the jurisdiction, I can list specific candidates
Reply with the market you care about (US, EU, UK, or “global”), and I’ll provide a candidate-by-candidate snapshot of Skyrizi biosimilars reported as in development, including the company, target filing status (where available), and any timing constraints tied to patents/exclusivity.
Sources:
[1] https://www.drugpatentwatch.com/